6th Jan 2020 14:34
(Alliance News) - Pharmaceutical firm Clinigen Group PLC on Monday said it has partnered with biopharmaceutical company Orphazyme AS to introduce and administer an early access programme for Arimoclomol in patients with Niemann-Pick disease type C in the US.
Arimoclomol is an experimental drug created for the treatment of some genetic disorders, including Niemann-Pick disease type C.
Clinigen said Orphazyme expects to submit to the US Food & Drug Administration for marketing approval of Arimoclomol in Niemann-Pick disease type C in the first half of 2020.
Clinigen was trading 0.4% higher in London on Monday at 922.50 pence each.
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L